Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • PMN310 | Amyloid-Beta
    • PMN267 | TDP-43
    • PMN442 | Alpha-Synuclein
    • Vaccines
    • Posters & Publications
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Mar 25, 2026

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

Mar 19, 2026

BriefGlance.com: ProMIS Unveils Precision Vaccines for ALS and Parkinson's Disease

Mar 18, 2026

ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)

Feb 4, 2026

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 30, 2026

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

Facebook Linkedin Spotify Twitter
©2026 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy